INSIGHT BANK · 28 LIVING CARDS
Follow a question.
See what changes.
Evidence, technologies, people and the next test—connected, but not confused.
Commercializationv4 · 09.23
How far will broader coverage translate into new screening and diagnostic follow-up?
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
- ✓Policy announcementRecorded
- ◷January 2027 implementationScheduled
- ?Testing and paymentUnverified
- ?Follow-up colonoscopyUnverified
Additional source checkedAdded planned EviCore implementation; prior clinical-performance assessment is unchanged.
NEXT CHECKTrack implementation, tests and payments, participation by previously unscreened people, and completed follow-up colonoscopies separately.
Commercializationv3 · 09.07
Where might linked diagnostic and therapy approvals stall in practice?
Concurrent approvals. Uptake and payment for the new use remain open.
- ✓Drug & CDxRecorded
- ?UptakeUnverified
- ?PaymentUnverified
- ?Real-world useUnverified
Analysis addedAdded a short reading on treatment-switch timing, ongoing monitoring and the practical and payment conditions for adoption.
NEXT CHECKConfirmatory trials, payer policies for the new use and clinical uptake.
Commercializationv3 · 10.13
After a candidate is found, how far is it validated, and who retains rights to the results?
The existing comparison of experimental services and rights to discovery assets now includes Ginkgo’s contribution of lab time and protein-testing services to NSF X-Labs.
- ✓Lab and testing support announcedRecorded
- ?Access terms and rightsUnverified
- ?Use and continuing demandUnverified
Additional source checkedAdded Ginkgo’s in-kind NSF X-Labs support, separated programme scale from company compensation, and identified usage and rights terms for follow-up.
NEXT CHECKUse of contributed capacity, experimental outcomes, access and data-reuse terms, and demand after the support ends.
Commercializationv1 · 09.29
How can molecular evidence of residual cancer guide postoperative treatment?
Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedRecorded a new question and follow-up checks from the approved manuscript.
NEXT CHECKTrack the authorized population and treatment conditions.
Commercializationv1 · 09.29
Which patients and product proposition could make a discontinued program viable?
As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedRecorded a new question and follow-up checks from the approved manuscript.
NEXT CHECKPatient selection, functional endpoints, long-term evidence and licensing terms.
Commercializationv2 · 10.13
How are costs, rights and returns shared when another company’s technology enables a treatment?
The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues.
- ✓PFS result announcedRecorded
- ?Prespecified OS assessmentUnverified
- ?Detailed resultsUnverified
Additional source checkedAdded the BNT113 PFS result and continuation of the prespecified OS assessment.
NEXT CHECKThe planned OS analysis, detailed PFS results, and explanations of the population and safety findings.
Commercializationv1 · 10.13
What benefit comes from detecting a resistance mutation and switching treatment before radiographic progression?
European certification was added for Guardant360 CDx. Earlier switching prolonged PFS in selected SERENA-6 patients, while SERENA-4 under different conditions missed its primary endpoint. FDA requires confirmation comparing early switching with switching at progression.
- ✓PFS benefit in selected patientsRecorded
- ?Compare early and progression-time switchingUnverified
- ?Long-term benefit and uptakeUnverified
New question openedLinked European CDx certification, SERENA-6, SERENA-4 and FDA confirmation requirements through the question of treatment timing.
NEXT CHECKComparison of early and post-progression use of the same drug, longer-term survival and uptake in the indicated population.
Commercializationv1 · 10.19
How much can easier administration contribute to treatment initiation and drug sales in thyroid eye disease?
The US approved Enspryng for adult thyroid eye disease. SatraGO-2 met its primary endpoint, whereas SatraGO-1 did not. Maintenance dosing is a subcutaneous injection every four weeks, with home administration possible after training.
- ✓New US indication approvedRecorded
- ?Track patient uptakeUnverified
- ?Compare indication-specific salesUnverified
New question openedRecord the new indication, the two trial outcomes and the administration route, and begin tracking uptake and indication-specific sales.
NEXT CHECKFollow disclosed new treatment starts, switches from other therapies and indication-specific sales in thyroid eye disease, separately from total Enspryng revenue.
Commercializationv1 · 10.24
At what quality, turnaround time and cost can patient-specific medicines be supplied repeatedly?
The company-reported phase 3 trial found two-year recurrence-free survival of 82.2% versus 70.0% after melanoma surgery. The expanded Tempus collaboration covers specimen collection and transfer, with sequencing subject to regulatory approvals.
- ✓Phase 3 results reportedRecorded
- ?Assess regulation and supplyUnverified
- ?Commercial scale and costsUnverified
New question openedRecord phase 3 results and supply roles, and track patient-level manufacturing and delivery conditions.
NEXT CHECKRegulatory decisions, specimen-to-delivery time, manufacturing success, per-patient costs and indication-specific outcomes.